The Presidential Commission for the Study of Bioethics has released its new report on the state of medical research, entitled “Moral Science – Protecting Participants in Human Subjects Research." But Matt Lamkin at the Stanford Law and Biosciences Blog writes that the Commission missed the mark. "The problem is not that the Commission failed to carry out its mandate," he writes, "but that its mandate was circumscribed in a way that all but precluded the Commission from addressing the most egregious abuses currently being inflicted on many human research subjects." Those abuses are taking place not in federally sponsored research, but in research sponsored by the pharmaceutical industry. Lamkin continues: "Although examining industry-funded research may have been beyond the scope of its charge, the Commission certainly wasn’t obligated to treat the pharmaceutical industry as a paragon of medical ethics, or to credulously accept the testimony of industry representatives about their ethical practices."
Read the entire post here.